FDC or isomers: C0 > 5 % of Cmax [Regulatives / Guidelines]

posted by Achievwin – US, 2024-08-05 21:08 (240 d 23:40 ago) – Posting: # 24134
Views: 2,244

❝ The ICH’s M13A will soon supersed the FDA’s guidance. However, a similar procedure is stated in its Section 2.2.3.3 Carry over.


❝ The idea of assessing the predose concentrations in higher period(s) is to check whether the washout was sufficiently long. The treatment comparison in the presence of equal/unequal carryover would – unavoidably – be biased and there is no statistical method to adjust for it.


Oh my equal/unequal carryover – never ending story

Complete thread:

UA Flag
Activity
 Admin contact
23,412 posts in 4,923 threads, 1,668 registered users;
112 visitors (0 registered, 112 guests [including 7 identified bots]).
Forum time: 20:49 CEST (Europe/Vienna)

Genius is that which forces
the inertia of humanity to learn.    Henri Bergson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5